Structure Therapeutics Inc. (GPCR) Income Statement
GPCR 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsGPCR revenue and net income
GPCR growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
GPCR quarterly EPS vs estimates
Structure Therapeutics beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.51).
GPCR income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $3.9M | $2.6M | $949,174 | $623,258 | $266,353 | $20,034 |
| Gross profit | −$3.9M | −$2.6M | −$949,174 | −$623,258 | −$266,353 | −$20,034 |
| Research & development | $225.3M | $108.8M | $70.1M | $36.2M | $29.1M | $12,364 |
| Sales, general & admin | $61.6M | $49.4M | $32.7M | $16.4M | $8.6M | $3,542 |
| Total operating expenses | $283.7M | $158.2M | $102.8M | $52.6M | $37.7M | $15,906 |
| Operating income | −$287.6M | −$158.2M | −$102.8M | −$52.6M | −$37.7M | −$15,906 |
| Interest expense | — | — | $13.4M | $1.5M | $122,161 | $5 |
| Income before taxes | −$140.7M | −$122.2M | −$89.4M | −$51.3M | −$37.8M | −$15,738 |
| Income taxes | $515,000 | $310,000 | $236,000 | $17,000 | $231,000 | $138 |
| Net income | −$141.2M | −$122.5M | −$89.6M | −$51.3M | −$40.0M | −$15,876 |
| EBITDA | −$139.4M | −$121.2M | −$75.7M | −$52.3M | −$37.6M | −$15,906 |
| EPS (diluted) | −$1.49 | −$0.78 | −$1.19 | −$1.14 | −$1.09 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $1.8M | $0 | $0 | $0 | $1.3M | $0 |
| Cost of revenue | — | $1.2M | — | — | $853,991 | $686,976 | $890,663 | $267,175 | $231,736 | $658,927 | $280,918 | $351,022 |
| Gross profit | — | −$1.2M | — | — | −$853,991 | −$686,976 | $890,663 | −$267,175 | −$231,736 | −$658,927 | $1.0M | −$351,022 |
| Research & development | $100.1M | $66.7M | $68.7M | $59.0M | $54.7M | $42.9M | $33.5M | $32.6M | $22.1M | $20.7M | $20.0M | $17.5M |
| Sales, general & admin | $18.6M | $22.9M | $17.6M | $14.8M | $15.7M | $13.4M | $13.6M | $13.2M | $11.3M | $11.3M | $11.2M | $8.6M |
| Total operating expenses | $118.6M | $88.4M | −$24.0M | $73.8M | $70.5M | $56.3M | $47.1M | $45.8M | $33.3M | $32.0M | $31.0M | $26.1M |
| Operating income | −$118.6M | −$89.6M | $24.0M | −$73.8M | −$70.5M | −$56.3M | −$47.1M | −$45.8M | −$33.3M | −$32.0M | −$31.0M | −$26.1M |
| Interest expense | — | — | — | — | — | — | — | — | — | $6.0M | $9.6M | $2.8M |
| Income before taxes | −$105.9M | −$76.0M | $33.2M | −$65.6M | −$61.5M | −$46.7M | −$36.3M | −$33.9M | −$26.0M | −$26.0M | −$24.8M | −$23.5M |
| Income taxes | $234,000 | $190,566 | $170,000 | $108,000 | $139,000 | $98,000 | $136,000 | $92,000 | $53,000 | $29,000 | −$312,000 | $405,000 |
| Net income | −$106.2M | −$76.2M | $33.0M | −$65.7M | −$61.7M | −$46.8M | −$36.5M | −$34.0M | −$26.0M | −$26.0M | −$24.5M | −$23.9M |
| EBITDA | −$105.4M | −$75.4M | $33.6M | −$65.2M | −$61.2M | −$46.5M | −$36.1M | −$33.6M | −$25.7M | −$25.8M | −$24.7M | −$23.4M |
| EPS (diluted) | −$0.49 | −$0.35 | −$0.49 | −$0.37 | −$0.36 | −$0.27 | −$0.21 | −$0.20 | −$0.18 | −$0.19 | −$0.53 | −$0.21 |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | 78.9% | — |
| Operating margin | — | — | — | — | — | — | −2,641.9% | — | — | — | −2,330.4% | — |
| Net margin | — | — | — | — | — | — | −2,047.9% | — | — | — | −1,842.4% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in GPCR's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
GPCR financial results
Structure Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $141.2 million. Diluted earnings per share came to −$1.49.
See the GPCR stock overview for the latest quote and news, or the GPCR chart for price history and technical indicators.
GPCR income statement FAQ
Does Structure Therapeutics have revenue?
Structure Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Structure Therapeutics profitable?
No. Structure Therapeutics reported a net loss of $141.2 million in fiscal 2025.
How much does Structure Therapeutics spend on research and development?
Structure Therapeutics spent $225.3 million on research and development in fiscal 2025.
What are Structure Therapeutics's earnings per share?
Structure Therapeutics earned $-1.49 per diluted share in fiscal 2025, compared with $-0.78 a year earlier.
When will Structure Therapeutics report its next earnings?
Structure Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does Structure Therapeutics's fiscal year end?
Structure Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.